The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Business Strategies of Generics Manufacturers Become Evident Ahead of Upcoming Round of Patent Expiries
August 13, 2012
- Asahi Kasei in Hot Pursuit of Eli Lilly Japan as Competition Heats Up in Market for Bone Formation Agents
August 13, 2012
- Astellas Concludes Marketing Agreement with Nippon Kayaku for Vascular Embolization Material
August 10, 2012
- Takeda Terminates PIII Trial for AMG 479 for Pancreatic Cancer in Japan
August 10, 2012
- Up to 50% of Doctors Know About “Established Products” as Recognition Levels Rise: Pfizer Survey
August 9, 2012
- Mylan Transfers Exclusive Rights to Pfizer to Market EpiPen in Japan
August 9, 2012
- Shionogi’s Korean Partner Obtains Approval for Pirespa
August 9, 2012
- Astellas Applies for Irribow OD Tablet
August 9, 2012
- Ethical Drug Sales Down 0.3% in June: Crecon Report
August 8, 2012
- Hospira Files Additional Indication for Precedex for Non-Intubated Patients
August 8, 2012
- Daiichi Sankyo to Strengthen Cardiovascular Field by Comarketing Diabetes Treatments, Focusing on SGLT-2 Inhibitor
August 8, 2012
- 6 Listed Wholesalers Post Low Price Settlement Rates as of End-June, Showing Declines Compared to 2 Years Earlier
August 7, 2012
- Astellas to Close US Subsidiary for Urology Research
August 7, 2012
- Fuji Pharma to Acquire Thailand’s Largest Contract Manufacturer, to Make It Base of Overseas Operations
August 7, 2012
- Japan BCG Laboratory, Nippon Kayaku to Copromote Immunobladder
August 7, 2012
- Astellas to “Seek Every Opportunity” for Domestic Vaccine Business, Including Alliances with Foreign Companies
August 6, 2012
- Astellas’s Sales Down 3.3% in April-June Due to Competition with Generics
August 6, 2012
- Takeda to Exclusively Distribute 7 J&J OTC Brands in Japan
August 6, 2012
- Eisai’s April-June Sales, Profits Show Double-Digit Decrease by NHI Price Reduction of Aricept
August 6, 2012
- Sanofi Pasteur Not Planning to Follow Request to Cut IPV Price: President Triomphe
August 3, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…